Has Linda Smith received payments from drug or device companies?

Yes. Drug and device makers reported $930 in general payments to Linda Smith across 36 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Linda Smith did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Linda Smith come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Linda Smith

Family · Painted Post, NYNPI 1063482149

Payments from drug & device makers

$930in general payments, 2019–2025

Across 36 payments — averaging $25.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$431
Si-bone, Inc.$97
Novo Nordisk$76
AbbVie$76
Pfizer$75
Exact Sciences$74
plus $102 from 3 others

What the payments were for

Food & beverage$930100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	15	$431
Si-bone, Inc.	1	$97
Novo Nordisk	4	$76
AbbVie	4	$76
Pfizer	4	$75
Exact Sciences	3	$74
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	3	$71
Lilly USA, LLC	1	$17
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BREZTRI$125

How this compares

$930 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.

See all family providers in New York →

Medicare billing

Part B allowed, 2024

$22,021

Medicare patients

Services billed

287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	48	$71,146
EliquisApixaban	58	$64,234
JardianceEmpagliflozin	51	$56,780
TrulicityDulaglutide	24	$47,902
FarxigaDapagliflozin Propanediol	18	$29,624
XareltoRivaroxaban	23	$29,185
JanuviaSitagliptin Phosphate	23	$26,262
Tresiba Flextouch U-200Insulin Degludec	14	$25,508
Breztri AerosphereBudesonide/Glycopyr/Formoterol	12	$14,501
TrintellixVortioxetine Hydrobromide	13	$6,674
SynthroidLevothyroxine Sodium	70	$5,924
Tresiba Flextouch U-100Insulin Degludec	12	$3,842
Novolog FlexpenInsulin Aspart	16	$3,809
Atorvastatin Calcium	221	$2,919
Metoprolol Succinate	138	$2,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic	$76	$71,14648 claims
PfizerEliquis	$75	$64,23458 claims
Lilly USA, LLCTrulicity	$17	$47,90224 claims
AstraZenecaFarxiga, Breztri Aerosphere	$431	$44,12530 claims
AbbVieSynthroid	$76	$5,92470 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,883 family providers in New York.